Neurokinin‐1 receptor: functional significance in the immune system in reference to selected infections and inflammation

The G protein–coupled receptor (GPCR), neurokinin‐1 receptor (NK1R), and its preferred ligand, substance P (SP), are reviewed in relationship to the immune system and selected infections. NK1R and SP are ubiquitous throughout the animal kingdom. This important pathway has unique functions in numerous cells and tissues. The interaction of SP with its preferred receptor, NK1R, leads to the activation of nuclear factor‐kappa B (NF‐κB) and proinflammatory cytokines. NK1R has two isoforms, both a full‐length and a truncated form. These isoforms have different functional significances and differ in cell signaling capability. The proinflammatory signals modulated by SP are important in bacterial, viral, fungal, and parasitic diseases, as well as in immune system function. The SP–NK1R system is a major class 1, rhodopsin‐like GPCR ligand–receptor interaction.

[1]  A. Lackner,et al.  Neurokinin-1 receptor (NK1-R) expression in the brains of SIV-infected rhesus macaques: implications for substance P in NK1-R immune cell trafficking into the CNS. , 2010, The American journal of pathology.

[2]  J. Weinstock,et al.  TGF-β regulates T-cell neurokinin-1 receptor internalization and function , 2010, Proceedings of the National Academy of Sciences.

[3]  D. Tweardy,et al.  Substance P Signaling Contributes to Granuloma Formation in Taenia crassiceps Infection, a Murine Model of Cysticercosis , 2010, Journal of biomedicine & biotechnology.

[4]  G. Cottrell,et al.  Endosomes: A legitimate platform for the signaling train , 2009, Proceedings of the National Academy of Sciences.

[5]  S. Douglas,et al.  Neurokinin 1 receptor isoforms and the control of innate immunity. , 2009, Trends in immunology.

[6]  D. Tweardy,et al.  Substance P is required for the pathogenesis of EMCV infection in mice. , 2009, International journal of clinical and experimental medicine.

[7]  Kendal G Cooper,et al.  Histoplasma capsulatum Encodes a Dipeptidyl Peptidase Active against the Mammalian Immunoregulatory Peptide, Substance P , 2009, PloS one.

[8]  S. Douglas,et al.  Substance P (SP) enhances CCL5‐induced chemotaxis and intracellular signaling in human monocytes, which express the truncated neurokinin‐1 receptor (NK1R) , 2008, Journal of leukocyte biology.

[9]  Peter Delves,et al.  Encyclopedia of life sciences , 2009 .

[10]  S. Douglas,et al.  Neurokinin‐1 Receptor Expression and Function in Human Macrophages and Brain , 2008, Annals of the New York Academy of Sciences.

[11]  D. Tweardy,et al.  Substance P Receptor Antagonism for Treatment of Cryptosporidiosis in Immunosuppressed Mice , 2008, The Journal of parasitology.

[12]  Neurokinin-1 receptor mRNA expression differences in brains of HIV-infected individuals , 2008, Journal of the Neurological Sciences.

[13]  S. Leeman,et al.  Differences in the length of the carboxyl terminus mediate functional properties of neurokinin-1 receptor , 2008, Proceedings of the National Academy of Sciences.

[14]  Xu Wang,et al.  Neurokinin-1 Receptor Antagonist (Aprepitant) Suppresses HIV-1 Infection of Microglia/Macrophages , 2008, Journal of Neuroimmune Pharmacology.

[15]  K. Bost,et al.  Neurogenic Exacerbation of Microglial and Astrocyte Responses to Neisseria meningitidis and Borrelia burgdorferi1 , 2008, The Journal of Immunology.

[16]  K. Lynch,et al.  Elevated substance P levels in HIV-infected women in comparison to HIV-negative women. , 2008, AIDS research and human retroviruses.

[17]  A. Cnaan,et al.  Detection of full-length and truncated neurokinin-1 receptor mRNA expression in human brain regions , 2008, Journal of Neuroscience Methods.

[18]  A. Goodman Neurobiology of addiction. An integrative review. , 2008, Biochemical pharmacology.

[19]  R. Di Fabio,et al.  Neurokinin 1 receptor antagonists--current prospects. , 2007, Current opinion in drug discovery & development.

[20]  C. Pothoulakis,et al.  Functional consequences of alteration of N-linked glycosylation sites on the neurokinin 1 receptor , 2007, Proceedings of the National Academy of Sciences.

[21]  P. Tebas,et al.  Neurokinin-1 Receptor Antagonist (Aprepitant) Inhibits Drug-Resistant HIV-1 Infection of Macrophages in vitro , 2007, Journal of Neuroimmune Pharmacology.

[22]  E. Reinke,et al.  Substance P receptor mediated maintenance of chronic inflammation in EAE , 2006, Journal of Neuroimmunology.

[23]  N. Page Characterization of the gene structures, precursor processing and pharmacology of the endokinin peptides. , 2006, Vascular pharmacology.

[24]  H. Satake,et al.  Overview of the primary structure, tissue-distribution, and functions of tachykinins and their receptors. , 2006, Current drug targets.

[25]  C. Palma Tachykinins and their receptors in human malignancies. , 2006, Current drug targets.

[26]  N. Singewald,et al.  The role of substance P in stress and anxiety responses , 2006, Amino Acids.

[27]  W. Ho,et al.  Full-length and truncated neurokinin-1 receptor expression and function during monocyte/macrophage differentiation , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[28]  W. Ho,et al.  Substance P and neurokinin-1 receptor modulation of HIV , 2004, Journal of Neuroimmunology.

[29]  F. Shanahan,et al.  The role of substance P in inflammatory disease , 2004, Journal of cellular physiology.

[30]  K. Bost,et al.  Expression of hemokinin 1 mRNA by murine dendritic cells , 2004, Journal of Neuroimmunology.

[31]  K. Bost,et al.  Non-neuronal mammalian tachykinin expression. , 2004, Frontiers in bioscience : a journal and virtual library.

[32]  D. Pascual The role of tachykinins on bacterial infections. , 2004, Frontiers in bioscience : a journal and virtual library.

[33]  K. Bost Tachykinin-mediated modulation of the immune response. , 2004, Frontiers in bioscience : a journal and virtual library.

[34]  K. Bost Tachykinin-modulated anti-viral responses. , 2004, Frontiers in bioscience : a journal and virtual library.

[35]  P. Nieto,et al.  Tachykinins and tachykinin receptors: structure and activity relationships. , 2004, Current medicinal chemistry.

[36]  D. Elliott,et al.  Cutting Edge: Hemokinin Has Substance P-Like Function and Expression in Inflammation1 , 2004, The Journal of Immunology.

[37]  Steven J. Greco,et al.  Tachykinins in the emerging immune system: relevance to bone marrow homeostasis and maintenance of hematopoietic stem cells. , 2004, Frontiers in bioscience : a journal and virtual library.

[38]  D. Pleasure,et al.  A non‐peptide substance P antagonist (CP‐96,345) inhibits morphine‐induced NF‐κB promoter activation in human NT2‐N neurons , 2004, Journal of neuroscience research.

[39]  C. Maggi,et al.  Tachykinins and tachykinin receptors: a growing family. , 2004, Life sciences.

[40]  S. Preskorn,et al.  Demonstration of the Efficacy and Safety of a Novel Substance P (NK1) Receptor Antagonist in Major Depression , 2004, Neuropsychopharmacology.

[41]  B. Graham,et al.  Contribution of respiratory syncytial virus G antigenicity to vaccine-enhanced illness and the implications for severe disease during primary respiratory syncytial virus infection , 2004, The Pediatric infectious disease journal.

[42]  Peter Holzer,et al.  Newly discovered tachykinins raise new questions about their peripheral roles and the tachykinin nomenclature. , 2004, Trends in pharmacological sciences.

[43]  J. Lachowicz,et al.  Identification of single-nucleotide polymorphisms of the human neurokinin 1 receptor gene and pharmacological characterization of a Y192H variant , 2004, The Pharmacogenomics Journal.

[44]  K. Conzelmann,et al.  Virokinin, a Bioactive Peptide of the Tachykinin Family, Is Released from the Fusion Protein of Bovine Respiratory Syncytial Virus* , 2003, Journal of Biological Chemistry.

[45]  N. Rupniak Animal models of depression: challenges from a drug development perspective. , 2003, Behavioural pharmacology.

[46]  Antagonists at the neurokinin receptors--recent patent literature. , 2003, IDrugs : the investigational drugs journal.

[47]  S. Hunt,et al.  Clinical and neuroinflammatory responses to meningoencephalitis in substance P receptor knockout mice. , 2003, Brain : a journal of neurology.

[48]  B. Adkins,et al.  Immunomodulatory effects of sensory nerves during respiratory syncytial virus infection in rats. , 2003, American journal of physiology. Lung cellular and molecular physiology.

[49]  Y. Hurd,et al.  Neurokinin 1 receptor and relative abundance of the short and long isoforms in the human brain , 2003, The European journal of neuroscience.

[50]  I. Gibbins,et al.  Cloning of a C-terminally truncated NK-1 receptor from guinea-pig nervous system. , 2003, Brain research. Molecular brain research.

[51]  Sherine F. Elsawa,et al.  Reduced CTL Response and Increased Viral Burden in Substance P Receptor-Deficient Mice Infected with Murine γ-Herpesvirus 681 , 2003, The Journal of Immunology.

[52]  D. Pleasure,et al.  Human neuronal cells (NT2‐N) express functional substance P and neurokinin‐1 receptor coupled to MIP‐1β expression , 2003, Journal of neuroscience research.

[53]  J. Galzi,et al.  Mutations in the Extracellular Amino-terminal Domain of the NK2 Neurokinin Receptor Abolish cAMP Signaling but Preserve Intracellular Calcium Responses* , 2002, The Journal of Biological Chemistry.

[54]  T. Ten Have,et al.  Association of depression with viral load, CD8 T lymphocytes, and natural killer cells in women with HIV infection. , 2002, The American journal of psychiatry.

[55]  Xu Wang,et al.  A non-peptide substance P antagonist down-regulates SP mRNA expression in human mononuclear phagocytes , 2002, Journal of Neuroimmunology.

[56]  Nadia M J Rupniak,et al.  New insights into the antidepressant actions of substance P (NK1 receptor) antagonists. , 2002, Canadian journal of physiology and pharmacology.

[57]  W. Ho,et al.  HIV enhances substance P expression in human immune cells , 2002, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[58]  Elucidating the antidepressant actions of substance P (NK1 receptor) antagonists. , 2002, Current opinion in investigational drugs.

[59]  A. Cnaan,et al.  Elevated substance P levels in HIV-infected men. , 2001, AIDS.

[60]  J. Findlay,et al.  Interaction of Met297 in the seventh transmembrane segment of the tachykinin NK2 receptor with neurokinin A. , 2001, The Journal of biological chemistry.

[61]  S. Edelstein,et al.  The Neurokinin A Receptor Activates Calcium and cAMP Responses through Distinct Conformational States* , 2001, The Journal of Biological Chemistry.

[62]  T. Schwartz,et al.  Two Active Molecular Phenotypes of the Tachykinin NK1 Receptor Revealed by G-protein Fusions and Mutagenesis* , 2001, The Journal of Biological Chemistry.

[63]  C. Montell,et al.  Assessment of the Role of the Inositol 1,4,5-Trisphosphate Receptor in the Activation of Transient Receptor Potential Channels and Store-operated Ca2+ Entry Channels* , 2001, The Journal of Biological Chemistry.

[64]  W. Ho,et al.  Substance P antagonist (CP-96,345) inhibits HIV-1 replication in human mononuclear phagocytes , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[65]  K. King,et al.  Exaggerated neurogenic inflammation and substance P receptor upregulation in RSV-infected weanling rats. , 2001, American journal of respiratory cell and molecular biology.

[66]  W. Ho,et al.  Detection of substance P and its receptor in human fetal microglia , 2000, Neuroscience.

[67]  M. S. Kramer,et al.  Update on Substance P (NK-1 receptor) antagonists in clinical trials for depression , 2000, Neuropeptides.

[68]  N. Bunnett,et al.  The proliferative and antiapoptotic effects of substance P are facilitated by formation of a beta -arrestin-dependent scaffolding complex. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[69]  W. Ho,et al.  Human stem cells express substance P gene and its receptor. , 2000, Journal of hematotherapy & stem cell research.

[70]  F. Shanahan,et al.  Differential Expression of Neurokinin-1 Receptor by Human Mucosal and Peripheral Lymphoid Cells , 2000, Clinical Diagnostic Laboratory Immunology.

[71]  M S Kramer,et al.  Discovery of the antidepressant and anti-emetic efficacy of substance P receptor (NK1) antagonists. , 1999, Trends in pharmacological sciences.

[72]  R. Raffa,et al.  Substance P antagonists: the next breakthrough in treating depression? , 1999, Journal of clinical pharmacy and therapeutics.

[73]  D. Elliott,et al.  Immunoregulation within the granulomas of murine schistosomiasis mansoni. , 1999, Microbes and infection.

[74]  R. Strieter,et al.  Acute and relapsing experimental autoimmune encephalomyelitis are regulated by differential expression of the CC chemokines macrophage inflammatory protein-1α and monocyte chemotactic protein-1 , 1998, Journal of Neuroimmunology.

[75]  E. Rappaport,et al.  Identification of a δ isoform of preprotachykinin mRNA in human mononuclear phagocytes and lymphocytes , 1998, Journal of Neuroimmunology.

[76]  S. Douglas,et al.  Serum levels of substance P are elevated in patients with sickle cell disease and increase further during vaso-occlusive crisis. , 1998, Blood.

[77]  R G Hill,et al.  Distinct mechanism for antidepressant activity by blockade of central substance P receptors. , 1998, Science.

[78]  W. Ho,et al.  Human lymphocytes express substance P and its receptor , 1998, Journal of Neuroimmunology.

[79]  C. Swain Neurokinin receptor antagonists. , 1998, Progress in medicinal chemistry.

[80]  W. Ho,et al.  Human monocytes and macrophages express substance P and neurokinin-1 receptor. , 1997, Journal of immunology.

[81]  G. Hauser,et al.  A substance P (neurokinin-1) receptor mutant carboxyl-terminally truncated to resemble a naturally occurring receptor isoform displays enhanced responsiveness and resistance to desensitization. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[82]  C. Maggi The effects of tachykinins on inflammatory and immune cells , 1997, Regulatory Peptides.

[83]  D. Perkins,et al.  Severe life stress as a predictor of early disease progression in HIV infection. , 1997, The American journal of psychiatry.

[84]  J. Burke,et al.  A substance P antagonist, RP-67,580, ameliorates a mouse meningoencephalitic response to Trypanosoma brucei brucei. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[85]  D. Payan,et al.  Identification of Potential Tyrosine-containing Endocytic Motifs in the Carboxyl-tail and Seventh Transmembrane Domain of the Neurokinin 1 Receptor* , 1997, The Journal of Biological Chemistry.

[86]  T. Schwartz,et al.  The dual nature of the tachykinin NK1 receptor. , 1997, Trends in pharmacological sciences.

[87]  P. Mantyh,et al.  Differential expression of two isoforms of the neurokinin-1 (substance P) receptor in vivo , 1996, Brain Research.

[88]  A. Cnaan,et al.  Substance P modulates human immunodeficiency virus replication in human peripheral blood monocyte-derived macrophages. , 1996, AIDS research and human retroviruses.

[89]  C. Maggi,et al.  The mammalian tachykinin receptors. , 1995, General pharmacology.

[90]  D. Perkins,et al.  Stress-associated reductions of cytotoxic T lymphocytes and natural killer cells in asymptomatic HIV infection. , 1995, The American journal of psychiatry.

[91]  D. Carney,et al.  Chemotherapy induced nausea and vomiting. , 1994, Irish medical journal.

[92]  J. Krause,et al.  Functional nonequivalence of structurally homologous domains of neurokinin-1 and neurokinin-2 type tachykinin receptors. , 1993, The Journal of biological chemistry.

[93]  S. Leeman,et al.  Biochemical Characterization of Two Different Forms of the Substance P Receptor in Rat Submaxillary Gland , 1993, Journal of neurochemistry.

[94]  K. B. Chou,et al.  Structure, expression and second messenger-mediated regulation of the human and rat substance P receptors and their genes , 1992, Regulatory Peptides.

[95]  C. Strader,et al.  cDNA sequence and heterologous expression of the human neurokinin-3 receptor. , 1992, Biochemical and biophysical research communications.

[96]  E. Kawashima,et al.  Molecular characterisation, expression and localisation of human neurokinin‐3 receptor , 1992, FEBS letters.

[97]  S. Nakanishi,et al.  The primary structure and gene organization of human substance P and neuromedin K receptors. , 1992, European journal of biochemistry.

[98]  K. Tsuchida,et al.  Direct linkage of three tachykinin receptors to stimulation of both phosphatidylinositol hydrolysis and cyclic AMP cascades in transfected Chinese hamster ovary cells. , 1992, The Journal of biological chemistry.

[99]  C. Strader,et al.  Differential activation of intracellular effector by two isoforms of human neurokinin-1 receptor. , 1992, Molecular pharmacology.

[100]  L. Garraway,et al.  Human substance P receptor (NK-1): organization of the gene, chromosome localization, and functional expression of cDNA clones. , 1991, Biochemistry.

[101]  I. Briggs,et al.  Isolation and characterisation of the human lung NK-1 receptor cDNA. , 1991, Biochemical and biophysical research communications.

[102]  K. B. Chou,et al.  Molecular cloning, structural characterization and functional expression of the human substance P receptor. , 1991, Biochemical and biophysical research communications.

[103]  A. Saltzman,et al.  Cloning, Expression of the Human Substance K Receptor, and Analysis of Its Role in Mitogenesis , 1991, Annals of the New York Academy of Sciences.

[104]  J. Lowe,et al.  A potent nonpeptide antagonist of the substance P (NK1) receptor. , 1991, Science.

[105]  R. Eddy,et al.  The human neurokinin A (substance K) receptor. Molecular cloning of the gene, chromosome localization, and isolation of the cDNA from tracheal and gastric tissues. , 1990, The Journal of biological chemistry.

[106]  A. Saltzman,et al.  Cloning and expression of the human substance K receptor and analysis of its role in mitogenesis. , 1991, Cell growth & differentiation : the molecular biology journal of the American Association for Cancer Research.

[107]  S. Nakanishi,et al.  Cloning and expression of a rat neuromedin K receptor cDNA. , 1990, The Journal of biological chemistry.

[108]  S. Nakanishi,et al.  Molecular characterization of mammalian tachykinin receptors and a possible epithelial potassium channel. , 1990, Recent progress in hormone research.

[109]  S. Nakanishi,et al.  Molecular characterization of a functional cDNA for rat substance P receptor. , 1989, The Journal of biological chemistry.

[110]  E. Brodin,et al.  Increased levels of substance P and cholecystokinin in rat cerebral cortex following repeated electroconvulsive shock and subchronic treatment with a serotonin uptake inhibitor. , 1989, Acta physiologica Scandinavica.

[111]  C. Boehmer,et al.  Substance P receptor binding sites are expressed by glia in vivo after neuronal injury. , 1989, Proceedings of the National Academy of Sciences of the United States of America.

[112]  J. Glowinski,et al.  Tachykinin Receptors of the NK1 Type (Substance P) Coupled Positively to Phospholipase C on Cortical Astrocytes from the Newborn Mouse in Primary Culture , 1989, Journal of neurochemistry.

[113]  P. Mantyh,et al.  Receptor binding sites for substance P, but not substance K or neuromedin K, are expressed in high concentrations by arterioles, venules, and lymph nodules in surgical specimens obtained from patients with ulcerative colitis and Crohn disease. , 1988, Proceedings of the National Academy of Sciences of the United States of America.

[114]  E. Brodin,et al.  Effects of subchronic treatment with imipramine, zimelidine and alaproclate on regional tissue levels of substance P-and neurokinin a/neurokinin B-like immunoreactivity in the brain and spinal cord of the rat , 1987, Neuropharmacology.

[115]  S. Nakanishi,et al.  cDNA eloping of bovine substance-K receptor through oocyte expression system , 1987, Nature.

[116]  H. Hartung,et al.  Substance P: binding properties and studies on cellular responses in guinea pig macrophages. , 1986, Journal of immunology.

[117]  J. Nurnberger,et al.  CSF substance P immunoreactivity in affective disorders , 1985, Biological Psychiatry.

[118]  M. Goedert,et al.  Mammalian tachykinin-induced hydrolysis of inositol phospholipids in rat brain slices. , 1985, Biochemical and biophysical research communications.

[119]  Roland S. G. Jones,et al.  Monoaminergic modulation of the sensitivity of neurones in the cingulate cortex to iontophoretically applied substance P , 1984, Brain Research.

[120]  T. Bártfai,et al.  Chronic treatment with the serotonin uptake inhibitor zimelidine elevates substance P levels in rat spinal cord. , 1984, Acta physiologica Scandinavica.

[121]  N. Barden,et al.  Perturbation of Rat Brain Serotonergic Systems Results in an Inverse Relation Between Substance P and Serotonin Concentrations Measured in Discrete Nuclei , 1983, Journal of neurochemistry.

[122]  L. Iversen,et al.  Substance P. , 1982, Journal of medicinal chemistry.

[123]  V. Erspamer The tachykinin peptide family , 1981, Trends in Neurosciences.

[124]  T. Hökfelt,et al.  Immunohistochemical evidence of substance P-like immunoreactivity in some 5-hydroxytryptamine-containing neurons in the rat central nervous system , 1978, Neuroscience.

[125]  S L Palay,et al.  Serotonin and substance P coexist i, neurons of the rat's central nervous system. , 1978, Proceedings of the National Academy of Sciences of the United States of America.

[126]  M. Chang,et al.  Amino-acid sequence of substance P. , 1971, Nature: New biology.

[127]  M. Chang,et al.  Isolation of a sialogogic peptide from bovine hypothalamic tissue and its characterization as substance P. , 1970, The Journal of biological chemistry.

[128]  J. Gaddum,et al.  An unidentified depressor substance in certain tissue extracts , 1931, The Journal of physiology.